- Patent Title: Antibody and binding fragment recognizing CACNA2D1 and use thereof
-
Application No.: US14001105Application Date: 2012-02-22
-
Publication No.: US10174123B2Publication Date: 2019-01-08
- Inventor: Zhiqian Zhang , Wei Zhao , Limin Wang , Haibo Han , Baocai Xing
- Applicant: Zhiqian Zhang , Wei Zhao , Limin Wang , Haibo Han , Baocai Xing
- Applicant Address: CN Beijing
- Assignee: Beijing Institute for Cancer Research
- Current Assignee: Beijing Institute for Cancer Research
- Current Assignee Address: CN Beijing
- Agency: Wolf, Greenfield & Sacks, P.C.
- Priority: CN201110042166 20110222
- International Application: PCT/CN2012/000227 WO 20120222
- International Announcement: WO2012/113266 WO 20120830
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K16/28 ; C12N5/20 ; C12N5/10 ; C12N15/85 ; A61K39/00 ; A61K39/395 ; A61K45/06 ; C12Q1/6886 ; G01N33/574 ; G01N33/68
Abstract:
Disclosed is a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method comprises a step of immunizing an animal using HEP-12 cells originating from a recurrent tumor and rich in originating cells. Also disclosed is a monoclonal antibody specially recognizing CACNA2D1 or antigen-binding fragments thereof, and the use thereof for treating or preventing tumors or diseases or conditions related to CACNA2D1.
Public/Granted literature
- US20140044729A1 ANTIBODY AND ANTIGEN RECOGNIZING TUMOR-INITIATING CELLS AND USE THEREOF Public/Granted day:2014-02-13
Information query
